Latest filing published 17 Sept 2026 for Enliven Therapeutics, Inc., €516k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Hohl Benjamin: trading record in brief
This profile gathers the share dealings of Hohl Benjamin in Enliven Therapeutics, Inc. Over a trading history stretching from 17 June 2026 to 17 September 2026, the count stands at 2 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The latest filing, published on 17 September 2026, reports a transaction of €516k in Enliven Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Hohl Benjamin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 12,036 shares@ US$49.12CommonSEC144:0001974158-26-000103
- 18,054 shares@ US$42.550.021% mcap52.7% of flowCommonSEC144:0001974158-26-000074
2 of 2 declarations
